X4 Pharmaceuticals Secures $60 Million in Financing, Names New Board and Management Team

Strategic Insights -

Boston-based biopharmaceutical company X4 Pharmaceuticals has announced a $60 million private placement in public equity (PIPE) financing led by Coastlands Capital, Bain Capital Life Sciences, and New Enterprise Associates. The financing is expected to support the company's continued development of its orally available CXCR4 antagonist, mavorixafor, and its commercialization in the U.S. for the treatment of certain chronic neutropenic disorders. Concurrent with the financing, the company has appointed a new board and management team, including Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as Chief Financial Officer.

The new management team brings extensive life science leadership experience, with Dr. Craig serving as an independent strategic advisor to multiple life science companies, including Interim Chief Executive Officer at Stratus Therapeutics and Chief Executive Officer of CTI BioPharma. John Volpone has over two decades of cross-functional drug development leadership experience in oncology and rare diseases, and David Kirske brings over two decades of strategic financial and operational experience, having served as Chief Financial Officer at Stratus Therapeutics and Executive Vice President and CFO of CTI BioPharma.

"We are excited to be joining X4 and for the opportunity to establish a world-class hematology company by unlocking the full commercial potential of mavorixafor," said Dr. Adam Craig, Executive Chairman of X4. "With the 4WARD Phase 3 study underway, there is a clear pathway for the potential approval of mavorixafor for the treatment of chronic neutropenia."

Key Takeaways:

  • X4 Pharmaceuticals has secured $60 million in financing from a private placement in public equity (PIPE) led by Coastlands Capital, Bain Capital Life Sciences, and New Enterprise Associates.
  • The financing is expected to support the company's continued development and commercialization of its CXCR4 antagonist, mavorixafor, for the treatment of certain chronic neutropenic disorders.
  • A new board and management team has been appointed, including Dr. Adam Craig as Executive Chairman, John Volpone as President, and David Kirske as Chief Financial Officer.
  • The management team brings extensive life science leadership experience, with a strong track record in the development and commercialization of life science products.
  • The company is evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial in people with certain chronic neutropenic disorders.

Statistics:

  • $60 million: The aggregate amount of proceeds to be received from the PIPE financing.
  • 11,040,776: The number of shares of common stock that X4 will issue at the closing of the PIPE financing.
  • $1.42: The purchase price per share of common stock.
  • $1.419: The pre-funded warrant price per share.
  • 31,234,731: The number of shares of common stock that may be purchased upon exercise of the pre-funded warrants.

Sources:

  • GlobeNewswire, "X4 Pharmaceuticals Announces $60 Million Private Placement in Public Equity (PIPE) Financing" (Aug. 12, 2025).
  • X4 Pharmaceuticals, "About Us" (accessed Aug. 12, 2025).